Health Care • Biotechnology: Pharmaceutical Preparations
$3.90 ▼ -0.13
(-3.23%)
MKT CAP: $55.4M • VOL: 34.3K
52W L $3 52W H $14
ROARABLE / RQD
E • 34/100
PIOTROSKI
3 / 9
CLNN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $200.0K | $342.0K | $654.0K |
| YoY Revenue Growth % | -41.5% | -47.7% | — |
| Gross Profit | $157.0K | $272.0K | — |
| Gross Margin % | 78.5% | 79.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.1M | -$33.1M | -$40.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$26.2M | -$39.4M | -$49.5M |
| EBITDA (Normalized) | -$23.1M | -$33.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.5M | -$21.3M | -$30.2M |
| Capital Expenditures (CapEx) | $39.0K | $15.0K | — |
| Free Cash Flow (FCF) | -$18.6M | -$21.3M | -$30.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.2M | $12.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$17.6M | -$8.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLNN.